A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

This study is looking for adults aged 18 to 75 who have Graves' disease. You would be considered if your thyroid is still overactive even though you are already taking medication for it. You also need to be able to understand what the study involves and be willing to follow the study plan.

However, some things might mean you can't join. For example, if you've already had a specific type of radiation treatment for your thyroid or have had your thyroid completely removed, you wouldn't be able to take part. Also, if you have other serious autoimmune conditions that need ongoing treatment, or if you have severe eye problems related to Graves' disease that need urgent treatment, this study might not be right for you. The study team will check all these details carefully.

If you decide to take part in this study, you'll be regularly seen by the study team. This will involve visits to the clinic where you'll have various check-ups, blood tests, and other assessments to monitor your health and how the treatment is affecting you. You'll be given either the new study medicine, IMVT-1402, or a dummy medicine called a placebo – you won't know which one you're receiving, and neither will your study doctor. This is standard practice in clinical trials to ensure fair testing.

You'll need to take the study medicine as instructed, and the team will explain exactly how to do this. There will be follow-up appointments over a period to see how you're doing after the main treatment phase. The research team will give you a detailed calendar of appointments and explain everything thoroughly before you agree to participate. The total duration of your participation will be explained to you.